Surgical Robots Market: Trends and Developments

The technological advancements in surgical robots, the increasing adoption of surgical robots, the various advantages of robotic-assisted surgery, and the increase in funding for medical robot research are the key drivers of the surgical robots market. Increasing penetration of surgical robots in ASCs and emerging markets are also supporting the growth of this market.

The Surgical Robots Market  is expected to reach USD 11.8 billion by 2025 from USD 6.7 billion in 2020, at a CAGR of 12.1%.

Ask for Free  PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=256618532

Market Segmentation: -

The surgical robots market is segmented based on product & service into robotic systems, instruments & accessories, and services. The instruments & accessories segment is expected to command the largest share of the market in 2020 and is estimated to grow at the highest CAGR during the forecast period. The recurrent purchase of instruments & accessories as opposed to robotic systems, which are a one-time investment, is the major factor driving the growth of this product segment.

The market is segmented into general surgery, urological surgery, gynecological surgery, orthopedic surgery, neurosurgery, and other applications based on applications. The general surgery applications segment is estimated to command the largest share of the market in 2020, and this segment is also projected to register the highest CAGR owing to increased use of surgical robots in general procedures such as bariatric surgery, Heller myotomy, gastrectomy, hernia repair, cholecystectomy, transoral surgery, and pancreatectomy.

Market Drivers: -
1 Advantages of Robotic-Assisted Surgery
2 Technological Advancements
3 Increasing Adoption of Surgical Robots
4 Increase in Funding for Medical Robot Research

Regional Analysis: -

North America is expected to dominate the global surgical robots market in 2020, the Asia Pacific region is expected to register the highest CAGR during the forecast period. The high growth in this region can be attributed to the increasing demand from key markets such as Japan and China and the large patient population in India. Due to this, the availability of robots has also grown in this region.

Request for Free Sample Pages - https://www.marketsandmarkets.com/requestsampleNew.asp?id=256618532

Top key Players: -

The major players operating in the surgical robots market include Intuitive Surgical (US), Stryker (US), and Medtronic (Ireland).

Healthcare CRM Market worth $17.4 billion by 2023

The benefits of CRM software and a growing focus on patient engagement are the major factors driving the growth of the healthcare CRM market.

The report Healthcare CRM Market is projected to reach USD 17.4 billion by 2023 from USD 8.8 billion in 2018, at a CAGR of 14.6% during the forecast period.

Ask for Free PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=88873203

Market Segmentation: -

Based on end user, the healthcare CRM market is segmented into healthcare providers, the life sciences industry, and healthcare payers. The healthcare providers segment is estimated to account for the largest share of the healthcare CRM market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Healthcare providers need to interact with multiple stakeholders, including patients, physicians, other referral healthcare organizations, healthcare payer organizations, pharmaceutical companies, and consumers/potential patients, and each requires unique CRM strategies and solutions. Moreover, there is a growing focus on patient engagement, which is again likely to drive the market for this segment.

On the basis of component, the healthcare CRM market is segmented into software and services. The services segment is expected to dominate the healthcare CRM market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Services form a large component of the healthcare CRM market primarily due to the indispensable role of service providers when it comes to the use of CRM solutions for healthcare. In terms of IT usage and skills, the healthcare industry is still in the nascent stage; it relies heavily on service providers for CRM-related services and support services, such as implementation, integration, training and education, maintenance, and technology upgrades. The recurring need for services such as software upgrades and maintenance is the key factor supporting the growth of this segment.

Regional Analysis: -

Geographically, the global healthcare CRM market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to hold the largest share of the healthcare CRM market. Some of the major factors driving the growth of this market include government initiatives and regulations to encourage the adoption of healthcare IT, growing pressure on healthcare organizations to focus on patient engagement for patient retention, growing EHR adoption, growing focus of CRM providers on developing and commercializing AI and analytics-powered advanced CRM solutions, and the increasing number of ACOs. However, the market in Asia is estimated to grow at the highest CAGR during the forecast period. Factors such as the improving quality of healthcare, improvements in healthcare systems, the growing medical tourism market in Asian countries, and increasing government initiatives are the key factors driving the growth of this market.

Request for Free Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=88873203  

Top Key Players: -

The key players in the healthcare CRM market are Salesforce.com, Inc. (US), SAP SE (Germany), Oracle (US), Microsoft (US), IBM (US), Influence Health (US), SugarCRM (US), Accenture (Ireland), Healthgrades (US), and Infor, Inc. (US).

Report explores the Infusion Pump Market worth $18.9 billion by 2025

The rising demand for ambulatory infusion pumps in home care settings, increasing incidence of chronic diseases along with the rapid growth of the geriatric population, and growing number of surgical procedures performed are the major fac

tors driving the growth of this market.

The global Infusion Pump Market is projected to reach USD 18.9 billion by 2025 from USD 13.5 billion in 2020, at a CAGR of 7.0% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=90374506 

Market Segmentation: -

Based on products, the Infusion Pumps Accessories Market is segmented into accessories & consumables and devices. The accessories & consumables segment is expected to grow at the highest CAGR during the forecast period.

Based on product, the infusion pumps market is segmented into dedicated accessories & consumables and non-dedicated accessories & consumables. The dedicated accessories & consumables segment is expected to grow at the highest CAGR during the forecast period.

Based on type, the Infusion Pumps Accessories Market has been segmented into traditional infusion pumps and specialty infusion pumps market. The specialty infusion pumps segment is expected to grow at the highest CAGR during the forecast period.

Based on application, the Infusion Pumps Accessories Market is segmented into chemotherapy/oncology, diabetes, gastroenterology, analgesia/pain management, pediatrics/neonatology, hematology, and other applications (includes infectious diseases, autoimmune diseases, and diseases of the heart, kidney, lung, and liver).

On the basis of end user, the infusion pumps market has been segmented into hospitals, home care settings, ambulatory care settings, and academic and research institutes.

Key Market Drivers: –
1 Rising demand for ambulatory infusion pumps in home care settings
2 Increasing incidence of chronic diseases along with the rapid growth of the geriatric population
3 Growing numbers of surgical procedures performed

Regional Analysis: -

North America accounted for the largest share of the infusion pumps market in 2019, followed by Europe.

Request for Sample Report: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=90374506

Key market Players: -

The prominent players in this market are Becton, Dickinson and Company (US), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Fresenius Kabi (Germany), ICU Medical, Inc. (US), Medtronic plc (Ireland), Mindray Medical International Limited (China), Micrel Medical Devices SA (Greece), and Ypsomed Holding AG (Switzerland), among other key players.

 

Stem Cell Therapy Market: Trends and Developments

Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global stem cell therapy market.

The Stem Cell Therapy Market is expected to reach USD 161.8 million by 2022, growing at a CAGR of 11.0% during the forecast period.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48

Market Segmentation: -

On the basis of mode of therapy, the global stem cell therapy market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. The allogeneic stem cell therapy segment is expected to command the largest share of 95.2% in the global stem cell therapy market in 2017 growing at a CAGR of 11.2% during the forecast period.

On the basis of therapeutic application, the global Stem Cell Therapy Industry is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of 61.1% in the global stem cell therapy market in 2017. Furthermore, the CVS diseases segment is expected to grow at the highest CAGR of 13.0% during the forecast period.

On the basis of cell source, the global Stem Cell Therapy Industry is divided into adipose derived MSCs, bone marrow derived MSCs, embryonic / cord blood SCs, and other cell sources. The adipose derived MSCs segment was expected to account for the largest share of 59.1% in the global stem cell therapy market in 2017.

Market Growth Drivers :-
1 Growing Awareness Related to the Therapeutic Potency of Stem Cells in Effective Disease Management
2 Development of Advanced Genome-Based Cell Analysis Techniques
3 Increasing Public-Private Investments for the Development of Stem Cell Therapies
4 Development in Infrastructure Related to Stem Cell Banking and Processing

Regional Analysis:-

North America is expected to be the largest regional segment in the global stem cell therapy market in 2017, followed by Asia-Pacific. In addition, the North American stem cell therapy market is expected to be the fastest growing region during the forecast period, growing at a CAGR of 11.5%.

Request for Sample Report :- 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=48

Key Market Players:-

As of 2016, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key players operating in the global stem cell therapy market.

 

Hematology Analyzers and Reagents Market: Trends and Developments

The increasing incidence of blood disorders and the growth in the number of blood donation are the major factors driving the growth of the global hematology analyzers and reagents market. Technological advancements in hematology analyzers and reagents and the integration of flow cytometry techniques with hematology analyzers are also expected to support the growth of this market during the forecast period.

The report Hematology Analyzers and Reagents Market  is projected to reach USD 10.6 billion by 2025 from USD 7.6 billion in 2020, at a CAGR of 6.9% during the forecast period.

Download PDF Brochure: –https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153222146

Market Segmentation: -

On the basis of products & services, the hematology reagents market is classified into hematology, hemostasis, and immunohematology products & services. The hematology products & services segment is projected to grow at the highest growth rate during the forecast period.

By end user, the hematology analyzers market is segmented into hospital laboratories, commercial service providers, government reference laboratories, and research & academic institutes. In 2019, the commercial service providers segment accounted for the largest share of the market due to factors such as the increasing awareness about hematology testing, shift from manual testing to automated testing, and the competitive benefits offered by these providers as compared to hospitals (such as affordable service costs, efficient turnaround time, and efficient management of sample collection).

Recent Developments: -

• In February 2018, Sysmex entered into an agreement with McKesson to distribute Sysmex’s XW-100 automated hematology analyzers in the US.
• In September 2017, Sysmex entered into an agreement with Mongolia’s Ministry of Health to provide technological, scientific, and external quality assessment support in the field of blood morphology to raise the accuracy of testing in the Mongolian region.
• Sysmex expanded its direct sales network in the Republic of Ghana (Africa) to reinforce its hematology sales and service structure in the African market.
• In July 2017, Sysmex launched XN-9100, XN-3100, XN-1500, and SP-50 (an automated hematology slide preparation unit).
• In July 2017, Sysmex launched the XN-L automated hematology analyzers in the US.

Regional Analysis: -

North America accounted for the largest share of the market in 2019. This can be attributed to the rising incidence of patients suffering from blood disorders, the growing prevalence of target diseases, and the rising demand for blood transfusions in the region.

Request for Sample Report: – https://www.marketsandmarkets.com/requestsampleNew.asp?id=153222146

Top key Players:-

The major players in the global hematology reagents market are Sysmex Corporation (Japan), Abbott Laboratories (US), Danaher Corporation (US), Nihon Kohden (Japan), Siemens (Germany), Boule Diagnostics (Sweden), HORIBA (Japan), Bio-Rad Laboratories (US), BioSystems (Spain), Diatron (Hungary), Drew Scientific (US), EKF Diagnostics (UK), Mindray (China), Ortho Clinical Diagnostics (US), and Roche (Switzerland).

Hemodialysis & Peritoneal Dialysis Market worth $99.2 billion by 2024

Growth in this market is driven by the increasing number of ESRD patients, growing prevalence of diabetes & hypertension, shortage of organ donors and risks associated with transplant, technological advancements and new product launches, and rising R&D expenditure for developing new dialysis products.

The report Hemodialysis & Peritoneal Dialysis Market  is projected to reach USD 99.2 billion by 2024 from USD 74.2 billion in 2019, at a CAGR of 6.0%.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1279

Market Segmentation:-

The global hemodialysis market is broadly categorized into two segments, namely, hemodialysis products and hemodialysis services market. The hemodialysis products market include machines (center-use & home-use machines) & consumables (dialyzers, access products, bloodlines, dialysates, and other consumables). The hemodialysis services (including in-center & home- hemodialysis services) segment is expected to account for the largest share of the hemodialysis market.

The peritoneal dialysis market, by modality, includes continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). The APD segment is expected to grow at the highest CAGR owing to its several advantages over CAPD, such as daytime freedom for patients, fewer connections and disconnections (and hence a lower probability of peritonitis), and improved quality of life. Being automated, APD is also the preferred dialysis treatment for the elderly and children.

Key Market Drivers: –
1 Increasing Number of ESRD Patients
2 Growing Prevalence of Diabetes and Hypertension
3 Shortage of Organ Donors and Risks Associated With Transplant
4 Technological Advancements and New Product Launches
5 Rising R&D Expenditure for Developing New Dialysis Products

Regional Analysis:-

Based on region, the hemodialysis and peritoneal dialysis market has been segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the hemodialysis and peritoneal dialysis market in 2019.

Request for Sample Report :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=1279

 Key Market Players:-

The major players operating in the global hemodialysis and peritoneal dialysis market are Fresenius Medical Care AG & Co. KGaA (Germany), DaVita Healthcare Partners, Inc. (US), Baxter International, Inc. (US), and B. Braun Melsungen AG (Germany).

Particle Size Analysis Market to Progress at a Healthy CAGR in Coming Years

Increasing research activities in the field of nanotechnology, rising investments in pharmaceutical R&D, and stringent regulatory guidelines for product quality across industries are fueling the growth of the market. Moreover, increasing government support for nanotechnology research and the rapidly growing pharmaceutical industry in emerging countries are some of the other major factors driving the growth of this market.

The Particle Size Analysis Market  is projected to reach USD 465 million by 2025 from USD 356 million in 2020, growing at a CAGR of 5.5% during the forecast period.

Download PDF Brochure: – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=74084833

Market segmentation: -

Based on technology, the market is segmented into laser diffraction, dynamic light scattering, imaging, coulter principle, nanoparticle tracking analysis, and other technologies. The laser diffraction segment accounted for the largest share of the particle size analysis market in 2019, driven by the growing initiatives to create awareness about laser diffraction, increasing R&D expenditure in the pharma and biotech sectors, and rising food safety concerns.

Based on type, the imaging market is segmented into two major types—dynamic imaging and static imaging.

The Nanoparticle Tracking Analysis (NTA) segment is expected to register the highest growth during the forecast period by technology. The significant growth of this segment is attributed to advanced applications of these particle size analyzers and growing research activities in the field of nanotechnology.

Recent Developments:

• In 2020, MICROTRAC MRB (US) entered into a distribution partnership with ATS Scientific (Canada), where ATS will act as a service provider for MICROTRAC in Canada.
• In 2019, Shimadzu Corporation (Japan), entered into an agreement with Earle A. Chiles Research Institute (Providence), (US). The agreement will focus on the application of mass spectrometry technology to develop tools for personalized cancer immunotherapeutics.
• In 2018, Malvern Panalytical (UK) and Waters Corporation (US) entered into a co-marketing agreement. Under this, both companies will market the polymer characterization product range.

Regional Analysis:-

The particle size analysis industry is segmented into five regional segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The North American region accounted for the largest share of the particle size analysis market in 2019.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=74084833

Top Key Players:-

The major players operating in the particle size analyzers market are Malvern Panalytical (UK), HORIBA (Japan), Beckman Coulter, (UK), MICROTRAC MRB, (US), Izon Science (UK), Micromeritics Instrument Corporation (US), Shimadzu Corporation (Japan), Sympatec (Germany), Anton Paar (Austria), TSI (US), Bettersize Instruments (China), FRITSCH (Germany), Brookhaven Instruments, (US), LS Instruments AG (Switzerland), and AimSizer (China).

Healthcare Interoperability Solutions Market: Trends and Developments

The major factors driving the growth of this market include the growing need to curb increasing healthcare costs and a growing focus on patient-centric care delivery. Moreover, government initiatives for enhancing patient care & safety and government funding for healthcare interoperability are also boosting market growth.

The Healthcare Interoperability Solutions Market is expected to reach USD 4.2 billion by 2024 from an estimated USD 2.3 billion in 2019, at a CAGR of 12.6%.

Download PDF Brochure: – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17705847

Market Segmentation:-

Based on type, the healthcare interoperability solutions market is segmented into software and services. The services segment is estimated to account for the largest market share in 2019. The large share of this segment can be attributed to the shifting era towards cloud computing and reduced operational costs for better and faster performance of business processes and applications.

Based on software type, the Interoperability solutions Market is segmented into EHR interoperability solutions, lab system interoperability solutions, imaging system interoperability solutions, HIE interoperability solutions, enterprise interoperability solutions, and other interoperability solutions. The HIE interoperability solutions segment is expected to grow at the highest CAGR during the forecast period.

Recent Developments:-

• In 2018, Epic launched the One Virtual System Worldwide, and added new features to its Care Everywhere solution.
• In 2016 Cerner opened a Health center at the Cerner Center in Bangalore, India, which helped the company enter the Indian market and also expand its geographic reach.
• In 2017, Epic launched its Share Everywhere.
• In 2016, Cerner launched its Open Developer Experience (code).

Regional Analysis:-

North America is expected to account for the largest share of the Interoperability solutions Market in 2019, followed by Europe. The dominance of the North American region can be attributed to the rising demand for quality healthcare delivery, a need to curb increasing healthcare expenditure, and the implementation of favorable initiatives & regulations to improve the overall efficiency of healthcare organizations in the region.

Speak To Analyst: – https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=17705847

Top Key Players:-

The prominent players in the Interoperability solutions Market are Cerner Corporation (US), Infor, Inc. (US), Allscripts Healthcare Solutions, Inc. (US), Koninklijke Philips NV (Netherlands), InterSystems Corporation (US), Orion Health Group Limited (New Zealand), iNTERFACEWARE (Canada), Quality Systems, Inc. (US), OSP Labs (US), Epic Systems Corporation (US), ViSolve, Inc. (US), and Jitterbit (US).

Mycoplasma Testing Market: Trends and Developments

The global mycoplasma testing markets growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments.

The global Mycoplasma Testing Market size is projected to reach USD 1,095 million by 2025 from USD 689 million in 2020, at a CAGR of 9.7%.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136509856

Market Segmentation: -

The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service. In 2019, the assays, kits, & reagents segment accounted for this markets largest share. The frequent purchase of these consumables compared to instruments and the increasing use of kit-based techniques for mycoplasma testing are the essential factors driving this market segments growth.

Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing. In 2019, the cell line testing segment accounted for the largest share of this market. Factors such as the rapid growth in the biopharmaceutical industry and the increasing demand for monoclonal antibodies drive this market segments growth.

Regional Analysis:-

The global mycoplasma testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the global mycoplasma testing market. The large share can be attributed primarily to the growth in biotechnology and pharmaceutical industries, the high adoption rate of novel technologies, and the large number of life science research studies conducted in this region.

Recent Developments

• In July 2020, Roche Diagnostics launched Cobas 6800, a fully automated system in India.
• In July 2020, Creative Bioarray launched a full range of cell-based services
• In January 2020, Charles River Laboratories (US) acquired HemaCare Corporation (US)

Speak To Analyst :- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=136509856

Top Key Players:-

The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Charles River Laboratories International, Inc. (US), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (US) and  Bionique Testing Laboratories, Inc. (US),

 

In-Vitro Diagnostics Market worth $96.0 billion by 2025

Factors such as the increased adoption of PoC IVD devices, rising elderly population base, and the growing number of infectious diseases are expected to drive the growth of the in-vitro diagnostics market.

The global In-Vitro Diagnostics Market size is projected to reach USD 96.0 billion by 2025 from USD 84.5 billion in 2020, at a CAGR of 2.6% during the forecast period.

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703

Market Segmentation: -

Based on products and services, the in vitro diagnostics market has been segmented into regents and kits, instruments, data management software and services. Within IVD market, reagents and kits accounted for the largest share in 2020. The large share of this segment can be attributed to the superior quality of reagents enabling accurate diagnosis and thus, having high preference amongst the healthcare professionals.

Based on end user, the in vitro diagnostics market has been segmented into hospitals, laboratories, patient self-testing, academia, point-of-care -testing others. The point-of-care testing segment is estimated to have enormous growth due to rising availability of highly efficient PoC kits. Recently launched point-of-care devices offer a precise diagnosis of chronic diseases that has raised its adoption in laboratories.

Key Market Drivers:-

1 Rising geriatric population and subsequent growth in the prevalence of chronic and infectious diseases.

2 Increasing adoption of fully automated and POC instruments in developed regions
3 Growing awareness regarding disease diagnosis in developing regions
4 Growing R&D investments by industry players to launch new IVD products

Regional Analysis :-

North America dominates the overall market based on region. This can be attributed to the rising geriatric population. Elderly population has comparatively weaker immunity and, therefore, is more susceptible to infections and other diseases. Furthermore, the regulatory scenario is quite stringent in the region that ensures the availability of defect-free IVD devices in the market that proves beneficial for market growth.

Speak To Analyst :- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=703

Top Key Players:-

The prominent players in the in vitro diagnostics market include Roche Diagnostics Limited (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific (US), Johnson & Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Sysmex Corporation (Japan), bioMérieux (France), Diasorin (Italy), Ortho-Clinical Diagnostics (US), and Qiagen (Germany).